VERAXA Biotech AG and Voyager Acquisition Corp. Announce $1.64 Billion Merger to Advance Cancer Therapies
VERAXA Biotech AG and Voyager Acquisition Corp. have agreed to a $1.64 billion merger, aiming to accelerate the development of innovative cancer therapies through VERAXA's Bi-Targeted Antibody Cytotoxicity platform.
The merger between VERAXA Biotech AG and Voyager Acquisition Corp. marks a significant step forward in the fight against cancer, with the combined entity valued at approximately $1.64 billion. This partnership is set to leverage VERAXA's proprietary Bi-Targeted Antibody Cytotoxicity (BiTAC) platform, which is at the forefront of developing dual-marker cancer therapeutics, including bispecific ADCs and T cell engagers. With nine programs in its pipeline and an active Phase 1 trial in leukemia, VERAXA is poised to make substantial contributions to oncology treatments.
The transaction, expected to close in Q4 2025, will see VERAXA trading on NASDAQ under the ticker symbol 'VERX'. Voyager's contribution of up to $253 million from its trust account will support VERAXA's operational and developmental goals. This merger not only highlights the growing importance of innovative cancer therapies but also underscores the potential of strategic partnerships in accelerating medical breakthroughs. The collaboration between VERAXA and Voyager could set a precedent for future mergers in the biotechnology sector, offering hope for patients worldwide.